Crescent Grove Advisors, LLC Amgen Inc Transaction History

Crescent Grove Advisors, LLC

$931 Million
Q1 2024

A detailed history of Crescent Grove Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, Crescent Grove Advisors, LLC holds 2,797 shares of AMGN stock, worth $865,335. This represents 0.09% of its overall portfolio holdings.

Number of Shares

2,797

Previous 2,797 -0.0%

Holding current value

$865,335

Previous $805,000 1.24%

% of portfolio

0.09%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 25, 2023	SELL	$218.65 - $271.46 $1,967 - $2,443	-9 Reduced 0.32%	2,797 $751,000
Q2 2023 Jul 13, 2023	BUY	$214.27 - $253.37 $6,428 - $7,601	30 Added 1.08%	2,806 $622,000
Q4 2022 Jan 12, 2023	BUY	$229.03 - $291.01 $2,748 - $3,492	12 Added 0.43%	2,776 $0
Q2 2022 Jul 20, 2022	SELL	$230.71 - $256.74 $50,756 - $56,482	-220 Reduced 7.37%	2,764 $672,000
Q1 2022 May 04, 2022	SELL	$219.27 - $242.57 $2,631 - $2,910	-12 Reduced 0.4%	2,984 $722,000

Q4 2021 Jan 24, 2022	BUY	$198.88 - $227.6 $143,193 - $163,872	720 Added 31.63%	2,996 $674,000
Q3 2021 Oct 26, 2021	BUY	$212.27 - $248.7 $83,634 - $97,987	394 Added 20.94%	2,276 $484,000
Q2 2021 Jul 26, 2021	BUY	$233.58 - $259.14 $2,802 - $3,109	12 Added 0.64%	1,882 $459,000
Q1 2021 May 07, 2021	BUY	$221.91 - $258.6 $22,856 - $26,635	103 Added 5.83%	1,870 $465,000
Q1 2019 May 13, 2019	SELL	$180.87 - $203.88 $542 - $611	-3 Reduced 0.17%	1,767 $336,000
Q4 2018 Jan 29, 2019	BUY	$178.4 - $208.25 $1,605 - $1,874	9 Added 0.51%	1,770 $345,000
Q3 2017 Nov 06, 2017	BUY	$167.29 - $191.0 $294,597 - $336,351	1,761	1,761 $328,000

Others Institutions Holding AMGN

# of Institutions

2,933

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $165B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crescent Grove Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crescent Grove Advisors, LLC with notifications on news.

Account

Crescent Grove Advisors, LLC Amgen Inc Transaction History